{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:53Z","timestamp":1791920153550,"version":"4.3.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["R\u00edo Hortega Contract (CM22\/00259)"],"award-info":[{"award-number":["R\u00edo Hortega Contract (CM22\/00259)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Type 2 diabetes (T2D) patients have an increased risk of heart failure (HF). There are limited data on the association between HF and T2D in specific healthcare settings. This study sought to analyse the prevalence and incidence of HF in a contemporary cohort of T2D patients attending cardiology and endocrinology outpatient clinics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted an observational multicentre prospective study (DIABET-IC) that enrolled patients with a T2D diagnosis attending cardiology and endocrinology outpatient clinics in 30 centres in Spain between 2018 and 2019. The prevalence at the start of the study and the incidence of HF after a 3\u00a0year follow-up were calculated. HF was defined as the presence of typical symptoms and either: a) LVEF\u2009&lt;\u200940%; or b) LVEF\u2009\u2265\u200940% with elevated natriuretic peptides and echocardiographic abnormalities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1249 T2D patients were included in the present analysis (67.6\u2009\u00b1\u200910.1\u00a0years, 31.7% female). HF was present in 490 participants at baseline (prevalence 39.2%), 150 (30.6%) of whom had a preserved ejection fraction. The presence of adverse social determinants and chronic conditions such as chronic kidney disease and atherosclerotic cardiovascular disease were more frequent in HF patients. During the study period, there were 58 new diagnoses of HF (incidence 7.6%) among those without baseline HF. The incidence rate was 3.0 per 100 person-years. Independent predictors of incident HF were smoking, left ventricular ejection fraction, NT-ProBNP, history of tachyarrhythmia and treatment with pioglitazone, oral anticoagulants, or diuretics. Despite an average suboptimal glycaemic control, the use of antidiabetic drugs with cardiovascular benefits was low (30.4% for sodium-glucose cotransporter-2 inhibitors and 12.5% for glucagon-like peptide-1 receptor agonists).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this contemporary cohort of T2D patients attending cardiology and endocrinology outpatient clinics, the prevalence and incidence of HF were high, comorbidities were frequent, and the use of antidiabetic agents with cardiovascular benefit was low. Outpatient care seems to be a unique opportunity for a comprehensive T2D approach that encompasses HF prevention, diagnosis, and treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12933-024-02358-0","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T19:01:53Z","timestamp":1721156513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort\u2014the DIABET-IC study"],"prefix":"10.1186","volume":"23","author":[{"given":"Rafael","family":"Gonzalez-Manzanares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Anguita-G\u00e1mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivencio","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Gimeno-Orna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rodr\u00edguez-Padial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Anguita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the DIABETIC-IC study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"2358_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027852","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu S, Yin X, et al. Trends burden inequalities of heart failure globally 1990 to 2019: a secondary analysis based on the global burden of disease 2019 study. J Am Heart Assoc. 2023. https:\/\/doi.org\/10.1161\/JAHA.122.027852.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2358_CR2","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jchf.2022.05.006","volume":"10","author":"R Bhatnagar","year":"2022","unstructured":"Bhatnagar R, Fonarow GC, Heidenreich PA, Ziaeian B. Expenditure on Heart Failure in the United States: the medical expenditure panel survey 2009\u20132018. JACC Heart Fail. 2022;10(8):571\u201380. https:\/\/doi.org\/10.1016\/j.jchf.2022.05.006.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2358_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12872-018-0815-3\/TABLES\/7","volume":"18","author":"W Lesyuk","year":"2018","unstructured":"Lesyuk W, Kriza C, Kolominsky-Rabas P. Cost-of-illness studies in heart failure: a systematic review 2004\u20132016. BMC Cardiovasc Disord. 2018;18(1):1\u201311. https:\/\/doi.org\/10.1186\/S12872-018-0815-3\/TABLES\/7.","journal-title":"BMC Cardiovasc Disord"},{"key":"2358_CR4","doi-asserted-by":"publisher","DOI":"10.21037\/amj.2020.03.03","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020. https:\/\/doi.org\/10.21037\/amj.2020.03.03.","journal-title":"AME Med J"},{"issue":"1","key":"2358_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/JEGH.K.191028.001","volume":"10","author":"MAB Khan","year":"2020","unstructured":"Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of type 2 diabetes\u2014global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107. https:\/\/doi.org\/10.2991\/JEGH.K.191028.001.","journal-title":"J Epidemiol Glob Health."},{"issue":"10397","key":"2358_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6.","journal-title":"Lancet"},{"issue":"10354","key":"2358_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5.","journal-title":"Lancet"},{"key":"2358_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-022-01575-9","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Drexel H, Jornayvaz FR, Pataky Z, Seferovi\u0107 PM, Wanner C. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022. https:\/\/doi.org\/10.1186\/S12933-022-01575-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2358_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4330\/WJC.V7.I3.119","volume":"7","author":"R Naito","year":"2015","unstructured":"Naito R, Kasai T. Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives. World J Cardiol. 2015;7(3):119. https:\/\/doi.org\/10.4330\/WJC.V7.I3.119.","journal-title":"World J Cardiol"},{"key":"2358_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/S12933-018-0728-6","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018. https:\/\/doi.org\/10.1186\/S12933-018-0728-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2358_CR11","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/J.CARDFAIL.2019.05.007","volume":"25","author":"SM Dunlay","year":"2019","unstructured":"Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America. J Card Fail. 2019;25(8):584\u2013619. https:\/\/doi.org\/10.1016\/J.CARDFAIL.2019.05.007.","journal-title":"J Card Fail"},{"issue":"1","key":"2358_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29\u201334. https:\/\/doi.org\/10.1016\/0002-9149(74)90089-7.","journal-title":"Am J Cardiol"},{"issue":"8","key":"2358_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S2213-8587(23)00128-6","volume":"11","author":"A Pandey","year":"2023","unstructured":"Pandey A, Khan MS, Patel KV, Bhatt DL, Verma S. Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes Endocrinol. 2023;11(8):607\u201324. https:\/\/doi.org\/10.1016\/S2213-8587(23)00128-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2358_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5603\/CJ.A2023.0016","volume":"31","author":"L Rodr\u00edguez-Padial","year":"2024","unstructured":"Rodr\u00edguez-Padial L, P\u00e9rez A, S\u00e1nchez MA, Barrios V, Orna JAG, Mu\u00f1iz J. Characteristics of women with type 2 diabetes and heart failure in Spain. The DIABET-IC study Cardiol J. 2024;31(1):103\u201310. https:\/\/doi.org\/10.5603\/CJ.A2023.0016.","journal-title":"The DIABET-IC study Cardiol J"},{"issue":"9596","key":"2358_CR15","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2358_CR16","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/DC18-S002","volume":"41","author":"Classification and Diagnosis of Diabetes","year":"2018","unstructured":"Classification and Diagnosis of Diabetes. Standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13\u201327. https:\/\/doi.org\/10.2337\/DC18-S002.","journal-title":"Diabetes Care"},{"issue":"27","key":"2358_CR17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/EURHEARTJ\/EHW128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129\u20132200m. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHW128.","journal-title":"Eur Heart J"},{"issue":"11","key":"2358_CR18","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","volume":"126","author":"RH Ritchie","year":"2020","unstructured":"Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501\u201325. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.315913.","journal-title":"Circ Res"},{"issue":"10","key":"2358_CR19","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/J.JCMG.2018.03.015","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yang H, Huynh Q, Nolan M, Negishi K, Marwick TH. Diagnosis of nonischemic stage B heart failure in type 2 diabetes mellitus: optimal parameters for prediction of heart failure. JACC Cardiovasc Imaging. 2018;11(10):1390\u2013400. https:\/\/doi.org\/10.1016\/J.JCMG.2018.03.015.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2358_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-10-29","author":"JB Somaratne","year":"2011","unstructured":"Somaratne JB, Whalley GA, Poppe KK, et al. Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community. Cardiovasc Diabetol. 2011. https:\/\/doi.org\/10.1186\/1475-2840-10-29.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"2358_CR21","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/S0735-1097(00)00582-9","volume":"35","author":"JS Gottdiener","year":"2000","unstructured":"Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35(6):1628\u201337. https:\/\/doi.org\/10.1016\/S0735-1097(00)00582-9.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2358_CR22","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.2337\/DC10-0286","volume":"33","author":"JP Van Melle","year":"2010","unstructured":"Van Melle JP, Bot M, De Jonge P, De Boer RA, Van Veldhuisen DJ, Whooley MA. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study. Diabetes Care. 2010;33(9):2084\u20139. https:\/\/doi.org\/10.2337\/DC10-0286.","journal-title":"Diabetes Care"},{"issue":"8","key":"2358_CR23","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/S00125-012-2579-0","volume":"55","author":"LJM Boonman-De Winter","year":"2012","unstructured":"Boonman-De Winter LJM, Rutten FH, Cramer MJM, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154\u201362. https:\/\/doi.org\/10.1007\/S00125-012-2579-0.","journal-title":"Diabetologia"},{"issue":"3","key":"2358_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1136\/JECH.54.3.173","volume":"54","author":"V Connolly","year":"2000","unstructured":"Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health. 2000;54(3):173\u20137. https:\/\/doi.org\/10.1136\/JECH.54.3.173.","journal-title":"J Epidemiol Community Health"},{"key":"2358_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/S12889-021-10919-1","author":"A Ohlsson","year":"2021","unstructured":"Ohlsson A, Eckerdal N, Lindahl B, Hanning M, Westerling R. Non-employment and low educational level as risk factors for inequitable treatment and mortality in heart failure: a population-based cohort study of register data. BMC Public Health. 2021. https:\/\/doi.org\/10.1186\/S12889-021-10919-1.","journal-title":"BMC Public Health"},{"issue":"12","key":"2358_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/HEARTJNL-2017-312539","volume":"104","author":"KK Witte","year":"2018","unstructured":"Witte KK, Patel PA, Walker AMN, et al. Socioeconomic deprivation and mode-specific outcomes in patients with chronic heart failure. Heart. 2018;104(12):993\u20138. https:\/\/doi.org\/10.1136\/HEARTJNL-2017-312539.","journal-title":"Heart"},{"issue":"8","key":"2358_CR27","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2468-2667(19)30108-2","volume":"4","author":"CA Lawson","year":"2019","unstructured":"Lawson CA, Zaccardi F, Squire I, et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health. 2019;4(8):e406\u201320. https:\/\/doi.org\/10.1016\/S2468-2667(19)30108-2.","journal-title":"Lancet Public Health"},{"key":"2358_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-022-06618-5","author":"SH Loosen","year":"2022","unstructured":"Loosen SH, Roderburg C, Curth O, et al. The spectrum of comorbidities at the initial diagnosis of heart failure a case control study. Sci Rep. 2022. https:\/\/doi.org\/10.1038\/S41598-022-06618-5.","journal-title":"Sci Rep"},{"issue":"4","key":"2358_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/J.RCENG.2021.04.005","volume":"222","author":"C Escobar","year":"2022","unstructured":"Escobar C, Varela L, Palacios B, et al. Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain. Rev Clin Esp. 2022;222(4):195\u2013204. https:\/\/doi.org\/10.1016\/J.RCENG.2021.04.005.","journal-title":"Rev Clin Esp"},{"issue":"10","key":"2358_CR30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","volume":"4","author":"V Nambi","year":"2016","unstructured":"Nambi V, Ballantyne CM, Hoogeveen RC, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol. 2016;4(10):840\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(16)30196-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2358_CR31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/JAMACARDIO.2016.3030","volume":"1","author":"BM Scirica","year":"2016","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2016;1(9):989\u201398. https:\/\/doi.org\/10.1001\/JAMACARDIO.2016.3030.","journal-title":"JAMA Cardiol"},{"issue":"11","key":"2358_CR32","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/EJHF.3036","volume":"25","author":"A Bayes-Genis","year":"2023","unstructured":"Bayes-Genis A, Docherty KF, Petrie MC, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25(11):1891\u20138. https:\/\/doi.org\/10.1002\/EJHF.3036.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2358_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/EJHF.2377","volume":"24","author":"M Obokata","year":"2022","unstructured":"Obokata M, Reddy YNV, Melenovsky V, Sorimachi H, Jarolim P, Borlaug BA. Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity. Eur J Heart Fail. 2022;24(2):353\u201361. https:\/\/doi.org\/10.1002\/EJHF.2377.","journal-title":"Eur J Heart Fail"},{"issue":"Suppl 1","key":"2358_CR34","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/DC24-S009","volume":"47","author":"Pharmacologic Approaches to Glycemic Treatment","year":"2024","unstructured":"Pharmacologic Approaches to Glycemic Treatment. Standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158\u201378. https:\/\/doi.org\/10.2337\/DC24-S009.","journal-title":"Diabetes Care"},{"key":"2358_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014908","author":"C Arnott","year":"2020","unstructured":"Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020. https:\/\/doi.org\/10.1161\/JAHA.119.014908.","journal-title":"J Am Heart Assoc"},{"issue":"10365","key":"2358_CR36","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C, Emberson JR, Haynes R, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8.","journal-title":"Lancet"},{"issue":"3","key":"2358_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/JCM10030505","volume":"10","author":"E Mart\u00edn","year":"2021","unstructured":"Mart\u00edn E, L\u00f3pez-Aguilera J, Gonz\u00e1lez-Manzanares R, et al. Impact of canagliflozin in patients with type 2 diabetes after hospitalization for acute heart failure: a cohort study. J Clin Med. 2021;10(3):1\u201311. https:\/\/doi.org\/10.3390\/JCM10030505.","journal-title":"J Clin Med"},{"issue":"7","key":"2358_CR38","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/J.RECESP.2012.02.019","volume":"65","author":"M Peir\u00f3","year":"2012","unstructured":"Peir\u00f3 M, Barrub\u00e9s J. New context and old challenges in the healthcare system. Rev Esp Cardiol. 2012;65(7):651\u20135. https:\/\/doi.org\/10.1016\/J.RECESP.2012.02.019.","journal-title":"Rev Esp Cardiol"},{"issue":"8","key":"2358_CR39","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/EURJPC\/ZWAC315","volume":"30","author":"CE Lim","year":"2023","unstructured":"Lim CE, Pasternak B, Eliasson B, Danaei G, Ueda P. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA\/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol. 2023;30(8):634\u201343. https:\/\/doi.org\/10.1093\/EURJPC\/ZWAC315.","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"2358_CR40","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1111\/DOM.15196","volume":"25","author":"D Abrahami","year":"2023","unstructured":"Abrahami D, D\u2019Andrea E, Yin H, et al. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. 2023;25(10):2980\u20138. https:\/\/doi.org\/10.1111\/DOM.15196.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"2358_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.SEMERG.2020.06.004","volume":"46","author":"R Gonz\u00e1lez Manzanares","year":"2020","unstructured":"Gonz\u00e1lez Manzanares R, Pericet Rodr\u00edguez C, Gallo Fern\u00e1ndez I, Castillo Dom\u00ednguez JC, Anguita SM. Heart failure hospitalization during COVID-19 pandemic. SEMERGEN. 2020;46(Suppl 1):91\u20132. https:\/\/doi.org\/10.1016\/J.SEMERG.2020.06.004.","journal-title":"SEMERGEN"},{"issue":"10","key":"2358_CR42","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/J.CJCA.2020.07.006","volume":"36","author":"C Frankfurter","year":"2020","unstructured":"Frankfurter C, Buchan TA, Kobulnik J, et al. Reduced rate of hospital presentations for heart failure during the COVID-19 pandemic in Toronto. Canada Can J Cardiol. 2020;36(10):1680\u20134. https:\/\/doi.org\/10.1016\/J.CJCA.2020.07.006.","journal-title":"Canada Can J Cardiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02358-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02358-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T19:02:30Z","timestamp":1721156550000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02358-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02358-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the Declaration of Helsinki and was approved by the lead centre clinical research ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"253"}}